UBS Group’s Bluejay Diagnostics BJDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$510 Buy
+149
New +$615 ﹤0.01% 10596
2026
Q2
– Sell
-31
Closed -$228 – 10458
2026
Q1
$228 Buy
+31
New +$306 ﹤0.01% 10017
2025
Q3
– Sell
-28
Closed -$764 – 10345
2025
Q2
$764 Sell
28
-23
-45% -$753 ﹤0.01% 9745
2025
Q1
$3.03K Sell
51
-71
-58% -$4.35K ﹤0.01% 9256
2024
Q4
$9.47K Buy
122
+45
+58% +$3.36K ﹤0.01% 8356
2024
Q3
$7.8K Buy
+77
New +$22.1K ﹤0.01% 7873
2023
Q3
– Hold
0
– -$1.36K – 9469
2023
Q2
– Hold
0
– – – 7938
2023
Q1
– Hold
0
– -$3.82K – 9619
2022
Q4
– Hold
0
– – – 9445
2022
Q3
– Hold
0
– – – 8403
2022
Q2
– Hold
0
– – – 10321
2022
Q1
– Hold
0
– – – 8951
2021
Q4
– Hold
0
– – – 8433

Other funds holding BJDX

UBS Group's BJDX Position: Q3 2026 in Review

UBS Group opened a new position in Bluejay Diagnostics (BJDX) in Q3 2026: 149 shares worth $510. The stake represents ﹤0.01% of the portfolio and ranks #10596 among its holdings. This is a return to the name: UBS Group previously reported a position in BJDX as recently as Q1 2026.

UBS Group first reported a position in BJDX in Q3 2024 and has held it in 6 quarters since. The position peaked at $9.47K in Q4 2024. 13 funds tracked by Wall St. Rank hold BJDX as of Q3 2026.

  • UBS Group held 149 shares of Bluejay Diagnostics worth $510 as of Q3 2026.
  • Bluejay Diagnostics was a new UBS Group position in Q3 2026.
  • Bluejay Diagnostics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10596 holding.
  • UBS Group first reported a position in Bluejay Diagnostics in Q3 2024 and has held it in 6 quarters since.
  • UBS Group's Bluejay Diagnostics position peaked at $9.47K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.